Verrica Pharmaceuticals Inc. Deferred Income Tax Expense (Benefit)
Verrica Pharmaceuticals Inc. (VRCA) reported Deferred Income Tax Expense (Benefit) of -$2.40 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-02.
Discontinued › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2022-03-02
- Verrica Pharmaceuticals Inc. deferred income tax expense (benefit) for fiscal 2021 was -$2.40M.
- Verrica Pharmaceuticals Inc. deferred income tax expense (benefit) for fiscal 2020 was -$2.40M.
| Period end | Deferred Income Tax Expense (Benefit) 12 month |
|---|---|
| 2021-12-31 | -$2.40M 10-K · filed 2022-03-02 |
| 2020-12-31 | -$2.40M 10-K · filed 2022-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |